自《“健康中国 2030”规划纲要》定调 “提高全民健康水平”,到“创新药”首次被写入《2025年政府工作报告》,以创新驱动国民健康水平提升,已成为国家战略的核心议题。在此背景下,中国本土药企的创新能力,成为衡量“健康中国”战略成色的关键。面对重大疾病治疗的需求缺口,中国药企正奋力蹚出一条从仿制到创新的“新质”路。在慢性髓性白血病(CML)治疗领域,翰森制药以深耕与引领之势,不仅一举击碎了进口药物...
Source Link自《“健康中国 2030”规划纲要》定调 “提高全民健康水平”,到“创新药”首次被写入《2025年政府工作报告》,以创新驱动国民健康水平提升,已成为国家战略的核心议题。在此背景下,中国本土药企的创新能力,成为衡量“健康中国”战略成色的关键。面对重大疾病治疗的需求缺口,中国药企正奋力蹚出一条从仿制到创新的“新质”路。在慢性髓性白血病(CML)治疗领域,翰森制药以深耕与引领之势,不仅一举击碎了进口药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.